Life Sciences Overview
We help global emerging life sciences companies
accelerate their product vision, FDA approval
and post approval processes, market execution
and senior exchange listing aspirations.
What we look for:
- Revolutionary Science
- Client traction
- Patient Acceptance
Our sweet spot
- Cap raise$ 15m – $ 100m
- Revenue$ pre – $ 100m (pre-revenue in emerging industries)
- Market cap$ 30m – $ 500m
- ExchangesNasdaq, NYSE, NEO
Our Life Sciences Team
Extensive life sciences business, capital formation, public market execution coupled with deep scientific expertise established through over 100 client engagements.
Managing Director, Life Sciences
John N. Bonfiglio, PhD
Marcus F. Keep, MD
Robert Miller, CFA
Life Sciences Advisory Overview
Broad capital markets capability sets, from IPO’s, direct listings and SPACS on senior exchanges such as NASDAQ and NYSE American to a broad range of financing options.
Scope of Services
End-to-end turnkey solutions, from the preparation, senior exchange filings and communication, financing capital markets strategy to post listing execution